Viatris(US:VTRS) Prnewswireยท2025-04-21 12:33Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors regarding the impact of a failed inspection at its Indore, India facility and a Warning Letter from the U.S. FDA, leading to a significant drop in stock price following the announcement of disappointing financial results [1][3]. Group 1: Lawsuit Details - The lawsuit covers purchasers of Viatris securities from August 8, 2024, to February 26, 2025, known as the "Class Period" [1]. - Investors learned of the misleading information on February 27, 2025, when Viatris announced its Q4 and full-year 2024 financial results, which included disappointing guidance for 2025 due to the expected financial impact from the Indore facility warning letter and import alert [3]. - Following this announcement, Viatris' stock price fell over 15%, dropping from $11.24 per share to $9.53 per share [3]. Group 2: Company Overview - Viatris is a healthcare company based in Canonsburg, PA, that supplies medicines to 1 billion patients globally [2]. - The company has faced scrutiny due to regulatory issues at its Indore facility, which have been highlighted in the lawsuit [3]. Group 3: Investor Information - Investors who purchased Viatris securities during the Class Period have until June 3, 2025, to seek appointment as a lead plaintiff representative of the class [2]. - A lead plaintiff acts on behalf of all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [4].